GSK3326595-Standard-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEGSK3326595(Standard)Cat.No.:HY-101563RCASNo.:1616392-22-3分⼦式:C₂₄H₃₂N₆O₃分⼦量:452.55作⽤靶点:ReferenceStandards;HistoneMethyltransferase;SARS-CoV;MDM-2/p53;CDK;Apoptosis作⽤通路:Others;Epigenetics;Anti-infection;Apoptosis;CellCycle/DNADamage储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性GSK3326595(Standard)GSK3326595(HY-101563)的分析标准品。本产品⽤于研究及分析应⽤。GSK3326595⼀种蛋⽩质精氨酸甲转移酶5(PRMT5)抑制剂，GSK3326595可减少SARS-CoV-2感染，抑制癌细胞增殖，诱导促炎巨噬细胞极化，并增加肝脏⽢油三酯⽔平，但不响动脉粥样硬化，可以⽤于复发/难治性套细胞淋巴瘤的研究[1][2][3][4]IC50&TargetIC50:6.2nM(PRMT5)[1]REFERENCES[1].LiZ,etal.GSK3326595isapromisingdrugtopreventSARS-CoV-2OmicronandothervariantsinfectionbyinhibitingACE2-R671di-

methylation[J].JournalofMedicalVirology,2023,95(1):e28158.[2].FedoriwA,etal.Anti-tumoractivityofthetypeIPRMTinhibitor,GSK3368715,synergizeswithPRMT5inhibitionthroughMTAPloss[J].

Cancercell,2019,36(1):100-114.e25.[3].ZhangY,etal.PRMT5inhibitioninducespro‐inflammatorymacrophagepolarizationandincreasedhepatictriglyceridelevelswithoutaffectingatherosclerosisinmice[J].JournalofCellularandMolecularMedicine,2023,27(8):1056-1068.[4].CheY,etal.ExploitingPRMT5asatargetforcombinationtherapyinmantlecelllymphomacharacterizedbyfrequentATMandTP53mutations[J].Bloodcancerjournal,2023,13(1):27.[5].LuoY,etal.Myelocytomatosis-proteinarginineN-methyltransferase5Axisdefinesthetumorigenesisandimmuneresponseinhepatocellularcarcinoma[J].Hepatology,2021,74(4):1932-1951.McePdfHeight1/1MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemECaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792